Daily Stock List
OWC Pharmaceutical Research Corp. (OWCP)
Promotion Stock Secrets, CFN Media Group, and Cannabis Financial Network News reported earlier on OWC Pharmaceutical Research Corp. (OWCP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OWC Pharmaceutical Research Corp. engages in the research and development (R&D) of cannabis-based medical products. The Company provides medical products for the treatment of different medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, and migraines; and also delivery systems. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research. OWC is based in Petach Tikva, Israel. The Company’s shares trade on the OTCQB.
One World Cannabis’ Research Division focuses on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of different medical conditions. Its Consulting Division’s commitment is to helping governments and companies navigate complex international cannabis regulatory frameworks. A medical cannabis R&D business, all of the Company’s research occurs at leading Israeli hospitals and scientific institutions, and are led by worldwide distinguished investigators.
OWC Pharmaceutical Research has entered into research and collaboration agreements with three of the top research institutions in Israel. These include Sheba Academic Medical Center, one of the top academic hospitals in the Middle East. These agreements serve as the basis for OWC’s clinical trials. They ensure that all of its studies have been, and will continue to be, founded on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.
OWC Pharmaceutical Research has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood through oral epithelial tissue.
In February, OWC Pharmaceutical Research announced that it received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical crème compound for the treatment of psoriasis and related skin conditions. The approval follows OWC’s February 1, 2017 8K filing announcing an extension to the size and scope of its efficacy study on the same compound that started in November 2016.
Yesterday, the Company announced that it received expressions of interest from the scientific and medical communities globally due to its recently announced positive preliminary clinical efficacy tests results of its topical cream to treat Psoriasis. OWC’s scientific team earlier reported trial results and concluded that with post-application of its unique, active cannabinoid-based topical cream formulation, there was up to 70 percent improvement in an array of inflammation markers directly associated with Psoriasis.
OWC Pharmaceutical Research Corp. (OWCP), closed Thursday's trading session at $0.98, down 4.85%, on 1,868,759 volume with 884 trades. The average volume for the last 60 days is 3,898,926 and the stock's 52-week low/high is $0.003/$3.23.
Sevion Therapeutics, Inc. (SVON)
InvestorsHub, TradingView, MarketWatch, Bloomberg, and Seeking Alpha reported on Sevion Therapeutics, Inc. (SVON), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
OTC Bulletin Board-listed, Sevion Therapeutics, Inc. is a biopharmaceutical company that discovers, develops, and acquires next-generation biologics. Sevion is building and developing a portfolio of innovative therapeutics, from internal discovery and acquisition, for the treatment of cancer and immunological diseases. Sevion Therapeutics has its headquarters in San Diego, California.
Sevion’s product candidates come from many key proprietary technology platforms - cell-based arrayed antibody discovery, ultralong antibody scaffolds, and Chimerasome nanocages. The Company has leveraged the technologies to build a pipeline of unique product candidates. Its antibody pipeline is undergoing development from technology that allows for the discovery of unique biologic therapies to previously inaccessible targets. This includes multispanning membrane proteins and ion channels, which play an important role in many diseases.
Additionally, Sevion has developed the first protein nanocage system enabling delivery of nucleic acids and other payloads to target cells. It is working together with CNA Development, LLC (an affiliate of Janssen Pharmaceuticals, Inc.) to discover antibodies using Sevion’s spatially addressed library platform. The collaboration facilitated by the Johnson & Johnson Innovation center in California will include discovery of antibodies against manifold targets in a number of therapeutic areas.
Sevion Therapeutics and Janssen Pharmaceuticals will jointly conduct research on antibodies discovered by Sevion. Janssen Pharmaceuticals will have an option to an exclusive license to develop, manufacture, as well as commercialize candidates resulting from the collaboration.
Regarding SVN-001 development, Sevion’s humanized cow antibody targeting the ion channel Kv1.3 for autoimmune disease was engineered to have a unique dual mode of action that has been confirmed in T-cell inhibitory assays. The potency of SVN-001 is in the subnanomolar range in vitro. Furthermore, the Company has its SVN-002, which is a unique antibody against an oncology target that holds the potential to significantly impact highly metastatic tumors that are resistant to anti-VEGF treatments.
Pertaining to Chimerasome Nanocages, the foundation of the Company’s Chimerasome technology is on a single protein that can be assembled to form a spherical protein nanocage encapsulating drugs or nucleic acid therapeutics. The Chimerasome can be coupled to antibodies or peptides externally, enabling highly-specific cellular targeting of the payload.
Regarding its Chimerasome Pipeline, Sevion has its SVN-003 product, which is a chimerasome/insulin product that preferentially delivers insulin to the liver. SVN-003 has extremely potent glucose regulation properties in animal models.
As concerns Partnering, the Company is studying opportunities to capitalize on its internally-generated assets, intellectual property (IP) and technology platforms, and also to in-license clinical stage assets that fit its pipeline. Moreover, Sevion is working with potential collaborators to take advantage of the IP around its nanocage delivery technology that has extensive applications across human health, agriculture, as well as biofuels.
Sevion Therapeutics, Inc. (SVON), closed Thursday's trading session at $0.175, up 6.06%, on 1,900 volume with 5 trades. The average volume for the last 60 days is 33,251 and the stock's 52-week low/high is $0.0791/$0.3033.
Gilla, Inc. (GLLA)
Marketbeat, StockBlogs, SmallCapVoice, SmallCapFinancialWire, Greenbackers, TopPennyStockMovers, and Real Pennies reported earlier on Gilla, Inc. (GLLA), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Gilla, Inc. manufactures, markets, and distributes E-liquid (the liquid used in vaporizers, and E-cigarettes) and other vaping hardware and accessories. E-cigarettes are increasingly being considered as an alternative to conventional tobacco cigarettes. They provide authentic smoking pleasure and do not burn tobacco. Nevertheless, they are not smoking cessation devices. Gilla’s goal is to be an international leader in delivering the most efficient and effective vaping solutions for nicotine and cannabis related products.
Gilla has its corporate office in Toronto, Ontario, and its manufacturing facility in Daytona Beach, Florida. Gilla has entered the cannabis industry with the introduction of its new brand of E-liquids featuring Cannabidiol (CBD). The Company’s new brand of CBD E-liquid products will be marketed under the new label "Enriched" and www.enrichedvapor.com.
Gilla's proprietary product portfolio includes Coil Glaze™, Siren, The Drip Factory, Craft Vapes™, Craft Clouds, Surf Sauce, Vinto Vape, and VaporLiq. Its portfolio also includes Vape Warriors, Vapor's Dozen, Miss Pennysworth's Elixirs, The Mad Alchemist™, Replicant, Enriched CBD, and Crown E-liquid™.
E-cigarettes and vaporizers are replacements for traditional cigarettes. E-cigarettes produce no offensive smells or second hand smoke. E-cigarettes enable smokers to reproduce the smoking experience. E-liquid is heated by the atomizer to deliver the sensation and taste of smoking.
Gilla continues to assess and pursue new business verticals, which complement its present expertise in the E-liquid and vapor products industry. Gilla has identified the cannabis concentrates sector as a feasible new business vertical. The Company is in the process of identifying and establishing relationships with existing operators worldwide for product licensing opportunities.
The Company is working to build and license a wide-ranging portfolio of cannabis concentrate products with a multi-jurisdictional distribution strategy that takes advantage of its existing sales and distribution platform along with its branding and expertise in E-liquid as a nicotine delivery solution.
Recently, Gilla announced that a subsidiary of the Company appointed Mr. Jason Provost to the position of Senior Vice President of Business Development. Mr. Provost has the main responsibility of advancing Gilla's entrance into the cannabis concentrate business.
He will oversee all aspects of Gilla's cannabis concentrate division. Mr. Provost will center on identifying and establishing relationships with existing operators globally for product licensing opportunities. Additionally, he will oversee the Company's product development in this area. This includes the creation and acquisition of specific intellectual property (IP) and knowledge regarding the production of the concentrates.
Gilla, Inc. (GLLA), closed Thursday's trading session at $0.1499, up 36.27%, on 1,775 volume with 2 trades. The average volume for the last 60 days is 17,137 and the stock's 52-week low/high is $0.0625/$0.22.
Defense Technologies International (DTII)
We are reporting on Defense Technologies International (DTII) today, here at the QualityStocks Daily Newsletter.
Defense Technologies International Corp. is a developer of security technologies. The Company previously went by the name Canyon Gold Corp. It changed its corporate name to Defense Technologies International Corp. in June of last year. Defense Technologies International is a holding company that includes Passive Security Scan, Inc. a wholly-owned subsidiary.
Defense Technologies International is headquartered in Las Vegas, Nevada. The Company lists on the OTC Markets’ OTCQB. Defense Technologies International acquired its wholly-owned subsidiary Defense Technology Corporation (DTC) in October 2015. DTC was established in 2007 to bring products to market in the areas of personal and collateral protection.
Defense Technologies International has started the final phase of production, and will be testing and marketing its New Passive Scanner Unit. The original prototype was successfully demonstrated and proven at the Science and Technology Offices of Homeland Security in Washington DC’s Offices.
The Company’s 'Offender Alert Passive Scan™' is a “next generation” walk-through detector scanning unit. The patented and trademarked passive scanning system allows for detecting and identifying concealed threats. This includes guns, knives, and more.
Defense Technologies International does not use X-rays to detect threats. The foundation of the scanner technology is on the ‘Earth Magnetic Fields’. Its Scanner has no emission whatsoever.
The Company’s subsidiary, 'Defense Technology Corporation' (DTC) is completing its final testing of its advanced metal detection device, The Offender Alert Passive Scan™. It will provide enhanced safety, particularly to schools, without any harmful effect to the students throughout their entire school life, due to the exclusive, advanced technology. It will equally serve sports stadiums and other venues nationwide and globally.
Future products for DTC include the Hand Held Passive Scan™. This hand-held wand unit is undergoing development (utilizing the same technology as the covert and free standing units) employing a battery power pack, which will allow an operator to “hand scan” a person safely.
Defense Technologies International announced this past November the successful test and demonstration of its Scanner Unit. The Company successfully completed the in-house test and demonstration of its New Passive Scanner alerting for metals, including those found in guns, knives, and more.
Last month, Defense Technologies International announced that it cut its corporate debt by close to a half million dollars. The Company reduced its liabilities by $436,773 and increased its capital by $920,420 during the months of November 2016 to January 31, 2017.
Defense Technologies International’s Chief Executive Officer, Mr. Merrill W. Moses, stated, "Defense Technologies remains committed to reducing liabilities and starting production of its Non-X-ray Scanner in the very near future. We appreciate and thank all our shareholders for their support."
Defense Technologies International (DTII), closed Thursday's trading session at $0.0072, up 20.00%, on 1,493,405 volume with 161 trades. The average volume for the last 60 days is 9,908,109 and the stock's 52-week low/high is $0.0055/$0.142.
Sutter Gold Mining, Inc. (SGMNF)
MarketWatch, Investing, InvestorsHub, and The Northern Miner reported previously on Sutter Gold Mining, Inc. (SGMNF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets Group’s OTCQB, Sutter Gold Mining, Inc. engages in the exploration of mineral properties. The Company mainly explores for gold deposits. Sutter Gold Mining has two projects. One is the Lincoln Project situated in Amador County, on the California Mother Lode Gold Belt. The other is the Santa Teresa Project situated in the Northern Baja region of Mexico. A Vancouver, British Columbia company, Sutter Gold Mining has its management office in Lakewood, Colorado.
The Company presently controls a substantial land position of the Mother Lode, in California. It has advanced work and exploration programs completed on surrounding land holdings.
Sutter Gold Mining placed the Lincoln Mine Project on care and maintenance in March of 2014. It did so while certain mineral processing issues were being evaluated and Sutter cut costs because of capital constraints.
The Company holds the rights to the geologically similar, high-grade El Alamo district of northern Baja In Mexico. This is where historic mining to the water table produced mined grades of 30 to 60 g/t gold.
Pertaining to Mexico and the Santa Teresa Concession, Sutter Gold Mining entered into an exclusive option agreement with The Alamo Group in October of 2006 to acquire a 100 percent interest in the Santa Teresa Mineral Concession. Santa Teresa is positioned in the historic El Alamo gold mining district, southeast of Ensenada. The property is located contiguous to and on strike with the past-producing Princessa Mine.
Sutter Gold released the assay results from the initial 32-hole Phase 1 program in January of 2009. The results included intercepts as high as 21.10 grams per ton or 0.62 ounces of gold per ton across 1.35 meters and 16.68 g/t of gold across 3.1 meters.
The results continued to reveal the potential of this underexplored district. In addition, the results confirmed numerous high-grade veins up to 260 meters along strike from the historic Princessa Gold Mine and that all known structures remain open in all directions.
Sutter Gold Mining, Inc. (SGMNF), closed Thursday's trading session at $0.038, up 15.15%, on 52,000 volume with 2 trades. The average volume for the last 60 days is 86,363 and the stock's 52-week low/high is $0.0287/$0.1309.
Players Network, Inc. (PNTV)
The QualityStocks Daily Newsletter would like to spotlight Players Network, Inc. (PNTV). Today, Players Network, Inc. closed trading at $0.035, up 3.24%, on 1,616,903 volume with 66 trades. The stock’s average daily volume over the past 60 days is 2,122,129, and its 52-week low/high is $0.0022/$0.048.
Players Network, Inc. (PNTV) is a diversified holding company operating in marijuana and media. PNTV owns 86% of Green Leaf Farms Holdings, LLC (Green Leaf Farms) which has Nevada state-issued cultivation and production license(s). The cultivation license enables Green Leaf Farms to grow marijuana and the production license enables them to create extracts which are used for cartridges, oils and edibles. WeedTV.com is a wholly owned subsidiary which is developing the ultimate resource for the marijuana lifestyle. PNTV has been a fully reporting, publicly traded company since 1998.
Green Leaf Farms Holdings, LLC (Green Leaf)
Green Leaf produces medical and recreational cannabis products. Revenues are generated by selling their cannabis products to licensed dispensaries throughout Nevada.
Their mission is to produce the highest quality and safest pharmaceutical-grade cannabis to all levels of consumers. They utilize the most efficient cultivation methods in order to lower expenses for consumers and to maximize returns for investors.
They are a privately held company with a unique business model as they are one of only a few companies who have been granted 2 (two) Medical Marijuana Establishment (MME) licenses in Nevada; Cultivation and Production.
Their Cultivation License enables them to grow cannabis which will produce flower. Their Production License enables them to process flower (cannabis) and cannabis byproducts into extremely pure concentrates, extracts, and oils which are used in medicine, cartridges and edibles. Green Leaf has both acquired and developed proprietary cannabis strains and will continue to be committed to cannabis research and development.
Green Leaf is located in North Las Vegas, Nevada on 2.3 acres in a state-of-the-art 26,000 sq. ft. facility. They have a seasoned team of professional growers and operators to manage the facility with proven best practices to ensure they have the highest quality products available.
WeedTV.Com is a niche social network and lifestyle channel destination for the marijuana industry. They are developing the "go-to" source for information, entertainment, products and services for people who relate to the marijuana lifestyle and an active social community. WeedTV.com features daily stories sourced by WeedTV.com correspondents and contributors from around the world.
Programming includes, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, the "Weed101" section, medical applications/issues, lifestyle features, and entertainment specials.
WeedTV.com's first original series is titled "High Stakes." High Stakes was developed by Michael Berk, the company's Chief Creative Officer and creator of one of the most popular cable series of all time, Baywatch. High Stakes is docu-series that follows the team at Green Leaf Farms as they build their facility and launch their marijuana business.
By leveraging media, WeedTV.com builds long-term brand equity and connects consumers to businesses. This is accomplished through fresh and relevant content such as professionally produced branded television segments, user-generated videos, blogs, editorials, tweets (twitter), photos, special offers, events and custom-designed contests to engage both consumers and businesses with their brands and services.
Marijuana and Media Strategy
While developing WeedTV.com, the PNTV team realized they could implement a vertical strategy to utilize their media platform (WeedTV.com) to drive business and awareness to their cannabis products (Green Leaf Farms). Through the audience and reach of WeedTV.com, they will build brand value and cross market their own marijuana products, as well as generate revenues by marketing other companies' products and services. Disclaimer
Players Network, Inc. Company Blog
Players Network, Inc. News:
Player's Network CEO Provides 1Q Shareholder Update, Outlook
Players Network (OTCQB: PNTV) Featured on MoneyTV with Donald Baillargeon, 2/17
Player's Network, Inc. Commences Trade on OTCQB
Singlepoint, Inc. (SING)
The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0505, off by 0.98%, on 1,493,405 volume with 161 trades. The stock’s average daily volume over the past 60 days is 9,908,109, and its 52-week low/high is $0.0055/$0.142.
NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), an NNW client focused on building its portfolio through the acquisition of, or investment in, small to mid-sized companies. The publication, "Marijuana Market Offers Variety of Investment Options and Consistent, Long-Lasting Growth Potential," shines a light on multiple cannabis-focused innovators and the diverse investment opportunities in the growing marijuana market. To view the full publication visit: https://www.networknewswire.com/marijuana-market-offers-variety-investment-options-consistent-long-lasting-growth-potential/
Singlepoint, Inc. (SING) provides mobile technology and marketing solutions that enable companies, nonprofits and religious organizations to conduct business transactions, accept donations, and engage in targeted communication via mobile devices. Through diversification of its own model, the company is also leveraging its core technology to expand into the mobile auctions and daily fantasy sports markets.
SING currently has two fundraising solutions. Text2Bid is an interactive way to increase auction revenues. The technology makes it easy for people to bid in auctions from any text or web-enabled phone. Donate by Text allows nonprofits to securely collect one-time or recurring donations via text. This capability creates a personal experience for the donors, and enables ongoing communication between the donor and nonprofit or event sponsor.
SING's payment solutions include point-of-sale (POS) terminals, loyalty programs, payment processing, phone services and financing. Pay by Text™ enables a business to accept payment transactions and, in essence, turns the user's mobile phone into a point-of-sale device. Operating on the same platform as mobile marketing, Pay by Text is designed to increase revenues, raise the average per-transaction amount, and create a fast, easy and hassle-free method of payment.
As part of its diversification and expansion strategy, SING recently acquired an interest in DraftFury (www.draftfury.com), a company that offers skill-based NBA, NFL and MLB daily fantasy sports (DFS) contests. DraftFury is known for its innovative offerings and originality, and is the first cash-flow-positive DFS enterprise. This transaction places SING in a multi-billion dollar industry expected to generate entry fees of $14.4 billion in 2020. Under the guidance of a leadership team well-versed in technology, engineering, marketing and raising capital, SING anticipates a strong foothold in its chosen markets. Disclaimer
Singlepoint, Inc. Company Blog
Singlepoint, Inc. News:
NetworkNewsWire Announces Publication Highlighting Several Investment Options in the Marijuana Market
NetworkNewsWire Announces Publication that Highlights Marijuana Stocks and Reviews the Economic Benefits Legalization
SinglePoint's Enterprise Strategy Diversifies the Company's Presence in the Cannabis Industry -- CFN Media
InMed Pharmaceuticals, Inc. (IMLFF)
The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.67, up 17.71%, on 4,844,502 volume with 2,430 trades. The stock’s average daily volume over the past 60 days is 960,565, and its 52-week low/high is $0.05/$0.579.
InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.
Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”
After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.
The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.
INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.
InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.
The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.
Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.
Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer
InMed Pharmaceuticals, Inc. Company Blog
InMed Pharmaceuticals, Inc. News:
InMed Pharmaceuticals' Unique Approach Featured in Forbes -- CFN Media
InMed's Exceptional Management Team Executes Ambitious Plan -- CFN Media
NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use
Bollente Companies, Inc. (BOLC)
The QualityStocks Daily Newsletter would like to spotlight Bollente Companies, Inc. (BOLC). Today, Bollente Companies, Inc. closed trading at $0.82, up 20.59%, on 4,550 volume with 5 trades. The stock’s average daily volume over the past 60 days is 8,771 and its 52-week low/high is $0.20/$1.07.
Bollente Companies, Inc. (BOLC) is in the early stages of developing a diverse portfolio of companies, targeting disruptive technologies that positively impact the environment and emerging economies. Their current focus is on high-efficiency electric tankless water heaters, manufactured and sold under "trutankless", a division of Bollente, including a line of economy tankless water heaters sold under the Vero name. Units are available for both residential and commercial application.
The primary Bollente advantage is their use of advanced technology, superior to previous tankless systems, together with a growing U.S. and global market. Traditional water heaters are one of the costliest appliances to operate. The two primary energy sources used in U.S. homes are electric and natural gas, with less than half of U.S. homes having natural gas available. In addition, there are no significant electric whole home tankless manufacturers.
The U.S. Department of Energy now requires tanks of 55 gallons or more to have efficiency levels requiring expensive heat pumps to achieve. Bollente's trutankless electric tankless water heater employs specialized sensors for constant water temperature, solid state electronics, and proprietary software, resulting in one of the most efficient heat exchangers ever produced. The technology includes smart grid and home automation capabilities, remote control and monitoring, and even smartphone alerts. It also allows adjustable custom power management settings, so that users can further enhance energy usage and performance. It is now estimated that tankless heaters used in every home would save over $8 billion annually in the U.S. alone.
By maintaining 99 percent efficiency, Bollente's trutankless heaters use less energy than tank heaters, while providing the convenience of always-hot water. The system only uses power when there is demand, producing water to exact temperature, within one degree, even with sudden changes to input. Wireless apps allow for remote settings, notifications, and monitoring, and models are compatible with existing home automation and energy management systems. The technology also reduces size, for easy location, and the system's self-flushing design provides up to 20+ years of maintenance free operation, significantly reducing upkeep and replacement costs. This becomes an additional environmental benefit since roughly 8 million used water heaters are dumped in landfills every year.
Bollente has also announced the formation of Bollente International, Inc., a wholly-owned subsidiary, for the international production and sale of trutankless systems. Taking advantage of growing interest in their technology, Bollente International is working with an international manufacturing firm for the production and distribution of trutankless systems throughout Europe, Asia, Australia and New Zealand, with the first step being the testing and certification necessary to meet the various international standards.
Bollente has made electric tankless water heating compelling to a major consumer market, both in and outside the U.S., offering economic as well as operational efficiency and convenience, attractive to builders as well as to end consumers. Disclaimer
Bollente Companies, Inc. Blog
Bollente Companies, Inc. News:
Award-Winning Luxury Builder Cullum Homes Makes trutankless® the Exclusive Water Heating Solution in its Communities
Bollente Companies, Inc. (BOLC) is “One to Watch”
Second Generation of Trutankless® Smart Water Heaters to Be Unveiled At International Builders Show
Dominovas Energy Corp. (DNRG)
The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0003, up 20.00%, on 28,677,580 volume with 38 trades. The stock’s average daily volume over the past 60 days is 17,409,559 and its 52-week low/high is $0.0002/$0.028.
Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.
At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.
In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.
Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer
Dominovas Energy Corp. Blog
Dominovas Energy Corp. News:
Dominovas Energy Obtains Partner to Facilitate Financing, Development and Production for RUBICON(TM) Fuel Cell Systems
Dominovas Energy Continues Discussions with Madagascar for Energy Projects
Dominovas Energy Secures Gas Supply for South Africa
Today's Top 3
Wall Street Mover
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Bollente Companies, Inc. (BOLC) Award-Winning Luxury Builder Cullum Homes Makes trutankless® the Exclusive Water Heating Solution in its Communities
- CD International Enterprises, Inc. (CDII) Enters Agreement to Distribute Cannabidiol, or CBD, in the United States
- ChineseInvestors.com, Inc. (CIIX) to Attend 'Invest 2017' Exhibition in Stuttgart, Germany
- Dominovas Energy Corp. (DNRG) Obtains Partner to Facilitate Financing, Development and Production for RUBICON(TM) Fuel Cell Systems
- eXp World Holdings, Inc. (EXPI) to Present at The MicroCap Conference on April 4th in New York
- GreenStone Healthcare Corp. (GRST) Buys Canadian Real Estate Assets, Sells Canadian Addiction Treatment Business, and Acquires Addiction Treatment Business in Florida
- India Globalization Capital, Inc. (NYSE: IGC) Sells Malaysian Hotel Investment Interest, Consolidates Corporate Focus on Development of Cannabis-Based Combination Therapies
- InMed Pharmaceuticals Inc. (IMLFF) Unique Approach Featured in Forbes -- CFN Media
- MGX Minerals Inc. (MGXMF) NetworkNewsWire Announces Publication that Reviews the Global Lithium Market and Discusses Innovators Rising to Meet Demand
- Monaker Group, Inc. (MKGI) to Present at the 29th Annual ROTH Conference, March 15, 2017
- National Waste Management Holdings, Inc. (NWMH) Expands Territory with Acquisition of Burts Refuse, LLC
- ORHub, Inc. (ORHB) NetworkNewsWire Announces Publication on Solutions for the Health Care Industry's Data Processing Needs
- ProBility Media Corp. (PBYA) Files 10Q, Reports Third Consecutive Quarter of Revenue Growth
- Players Network (OTCQB: PNTV) CEO Provides 1Q Shareholder Update, Outlook
- Singlepoint, Inc. (SING) NetworkNewsWire Announces Publication Highlighting Several Investment Options in the Marijuana Market
- Stealth Technologies, Inc. (STTH) Announces 5 New Products